Core Insights - ORIC Pharmaceuticals, Inc. is a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance [3] - The company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 11:15 a.m. ET [1] - A webcast of the fireside chat will be available on the company's investor website, with a replay accessible for 90 days post-event [2] Company Overview - ORIC Pharmaceuticals is dedicated to improving patients' lives by overcoming resistance in cancer [3] - The company's clinical stage product candidates include ORIC-944, an allosteric inhibitor targeting the polycomb repressive complex 2 (PRC2) for prostate cancer, and enozertinib (ORIC-114), a brain-penetrant inhibitor for various genetically defined cancers [3] - ORIC has offices located in South San Francisco and San Diego, California [3]

Summary of ORIC Pharmaceuticals Conference Call Company Overview - **Company Name**: ORIC Pharmaceuticals - **Ticker**: NasdaqGS:ORIC - **Focus**: Development of small molecule drugs in oncology, specifically targeting solid tumors like prostate cancer and lung cancer [2][3] Key Points and Arguments Lead Programs - ORIC is currently focused on two lead programs in prostate cancer and lung cancer, both in dose optimization and expected to start pivotal phase three studies in 2026 [2][3] ORIC-944 Program - Recent data showed encouraging results for the ORIC-944 program, particularly in combination with apalutamide and daralutamide, with impressive PSA response rates [3][4] - ORIC-944 has a 20-hour half-life compared to Pfizer's memoremedistat, which has a five-hour half-life, suggesting a potential safety advantage [3][19] - The ability to clear ctDNA was observed in 59% of patients, which correlates strongly with long-term outcomes like PFS and OS [5][9] Safety Profile - The safety profile of ORIC-944 appears favorable, with only one grade 3 adverse event reported in 20 patients, compared to multiple grade 3 events in Pfizer's studies [13][15] - A clean safety profile is crucial for future development, especially in earlier lines of treatment for prostate cancer [14][15] Market Opportunity - The metastatic CRPC market is estimated at approximately 50,000 patients, with a total addressable market (TAM) of about $3.5 billion in the US for each of the post-AR inhibitors and post-abiraterone populations [29][30] - Historical data suggests that even with an undifferentiated profile, a second-to-market drug can capture about 35% of the market [30] Future Development Plans - ORIC plans to submit dose optimization data to regulators in early 2026 to align on pivotal study design [25][26] - The first phase three study is expected to start in the first half of 2026, with primary readout anticipated in the second half of 2027 [27][28] Pipeline Asset ORIC-114 - ORIC-114 is focused on non-small cell lung cancer, with updates expected at ESMO Asia in December, including data from multiple cohorts [35] - The drug is designed to be CNS-penetrant, which may lead to longer PFS outcomes for patients with brain metastases [36][37] Financial Position - As of the third quarter, ORIC had $413 million in cash and investments, providing a runway into the second half of 2028, covering pivotal studies for both ORIC-944 and ORIC-114 [42] Additional Important Information - ORIC maintains strong relationships with Bayer and Johnson & Johnson, which are crucial for future collaborations [31][32] - The company is exploring the potential of PRC2 inhibitors in other oncology indications beyond prostate cancer, including breast cancer and lung cancer [33][34]

Core Viewpoint - Oric Pharmaceuticals, Inc. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, making it a valuable tool for investors [2][4]. - The recent upgrade reflects an improvement in Oric Pharmaceuticals' earnings outlook, which is expected to positively affect its stock price [3][5]. Earnings Estimate Revisions - For the fiscal year ending December 2025, Oric Pharmaceuticals is projected to earn -$1.61 per share, unchanged from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Oric Pharmaceuticals has increased by 6.6%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimates, with only the top 20% of stocks receiving a "Strong Buy" or "Buy" rating, highlighting their potential for market-beating returns [9][10]. - Oric Pharmaceuticals' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a favorable outlook for the stock in the near term [10].

Financial Performance - ORIC Pharmaceuticals reported a net loss of $99.0 million for the nine months ended September 30, 2025, with an accumulated deficit of $661.7 million[77]. - Other income, net for the nine months ended September 30, 2025, was $9.5 million, a decrease of $2.3 million from $11.8 million in the same period of 2024[89]. - ORIC Pharmaceuticals anticipates significant losses will continue as it advances its clinical programs, particularly ORIC-944 and enozertinib[77]. Research and Development Expenses - Research and development expenses for the three months ended September 30, 2025, were $28.8 million, a decrease of $2.4 million compared to $31.2 million in the same period of 2024[89]. - For the nine months ended September 30, 2025, research and development expenses increased to $84.0 million, up 2.3% from $82.1 million in the same period of 2024[91]. - Research and development expenses for Q3 2025 were $28.8 million, a decrease of 7.7% from $31.2 million in Q3 2024[90]. General and Administrative Expenses - General and administrative expenses increased to $7.9 million for the three months ended September 30, 2025, compared to $7.1 million in the same period of 2024[89]. - For the nine months ended September 30, 2025, general and administrative expenses rose to $24.5 million, a 15.6% increase from $21.2 million in the same period of 2024[94]. - General and administrative expenses for Q3 2025 were $7.9 million, an increase of 11.3% from $7.1 million in Q3 2024[93]. Operating Expenses - Total operating expenses for the nine months ended September 30, 2025, were $108.5 million, an increase of $5.1 million from $103.3 million in the same period of 2024[89]. Cash Flow and Financial Resources - Net cash used in operating activities for the nine months ended September 30, 2025, was $88.5 million, compared to $84.6 million in the same period of 2024[104]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $243.8 million, significantly higher than $126.0 million in the same period of 2024[110]. - As of September 30, 2025, the company had cash, cash equivalents, and investments totaling $413.0 million[116]. - The company expects its current financial resources to support operations into the second half of 2028[99]. - The company raised approximately $125.0 million from a private placement of common stock in May 2025[95]. - The company anticipates substantial additional capital will be required to develop product candidates and fund operations in the future[98]. Clinical Trials and Pipeline - ORIC-944 demonstrated a PSA50 response rate of 55% and a PSA90 response rate of 20% in patients with metastatic castration-resistant prostate cancer[74]. - Enozertinib is in a Phase 1b trial for advanced solid tumors, with initial data showing systemic and intracranial activity[75]. - A strategic pipeline prioritization was announced on August 12, 2025, resulting in a 20% workforce reduction and a one-time cost of approximately $1.9 million[85]. - The company expects to report dose optimization data for ORIC-944 in the first quarter of 2026 and initiate a Phase 3 trial in the first half of 2026[74].

Financial Position - ORIC Pharmaceuticals reported cash and investments of approximately $413 million, expected to fund operations into the second half of 2028[1]. - The company raised $108.7 million in net proceeds under the at-the-market (ATM) program during Q3 2025[7]. Research and Development - Research and development (R&D) expenses for Q3 2025 were $28.8 million, a decrease of 7.7% from $31.2 million in Q3 2024[10]. - Research and development expenses for Q3 2025 were $28.773 million, a decrease from $31.202 million in Q3 2024, while year-to-date R&D expenses increased to $83.962 million from $82.102 million[18]. - ORIC anticipates reporting four clinical data readouts across ORIC-944 and enozertinib programs through mid-2026[1]. - ORIC-944 demonstrated a 55% PSA50 response rate and a 20% PSA90 response rate in a Phase 1b trial involving 20 patients with metastatic castration-resistant prostate cancer[6]. - 76% of patients in the ORIC-944 trial achieved over 50% reduction in circulating tumor DNA (ctDNA), with 59% achieving ctDNA clearance[6]. - ORIC-944 is being developed in combination with darolutamide and apalutamide, with recommended Phase 2 doses set at 400 mg and 600 mg once daily[3]. - Enozertinib is expected to present data at ESMO Asia 2025 in December 2025, focusing on multiple patient cohorts[10]. Operating Expenses - General and administrative (G&A) expenses for Q3 2025 were $7.9 million, an increase of 11.3% from $7.1 million in Q3 2024[10]. - General and administrative expenses rose to $7.898 million in Q3 2025 compared to $7.116 million in Q3 2024, with year-to-date expenses increasing to $24.491 million from $21.223 million[18]. - Total operating expenses for Q3 2025 were $36.671 million, down from $38.318 million in Q3 2024, while year-to-date total operating expenses increased to $108.453 million from $103.325 million[18]. Net Loss and Income - The net loss for Q3 2025 was $32.587 million, slightly improved from a net loss of $34.566 million in Q3 2024, with year-to-date net loss increasing to $98.963 million from $91.540 million[18]. - The comprehensive loss for Q3 2025 was $32.159 million, compared to $33.588 million in Q3 2024, with year-to-date comprehensive loss at $98.727 million versus $91.076 million[18]. - Basic and diluted net loss per share for Q3 2025 was $0.33, an improvement from $0.49 in Q3 2024, while year-to-date loss per share decreased to $1.20 from $1.32[18]. - Other income for Q3 2025 was $4.084 million, an increase from $3.752 million in Q3 2024, with year-to-date other income decreasing to $9.490 million from $11.785 million[18]. Share Information - The weighted-average shares outstanding for Q3 2025 were 98,953,331, compared to 70,542,684 in Q3 2024, and year-to-date shares increased to 82,808,969 from 69,417,672[18]. Management Changes - The company appointed Kevin Brodbeck, PhD, as Chief Technical Officer to support late-stage development[5].

Core Insights - ORIC Pharmaceuticals announced the completion of the dose exploration portion of the ORIC-944 Phase 1b clinical trial, demonstrating potential best-in-class efficacy and safety [1][2] - The company appointed Kevin Brodbeck, PhD, as Chief Technical Officer to support the transition to late-stage development [1] - ORIC has approximately $413 million in cash and investments, expected to fund operations into the second half of 2028 [1][3] - Anticipated primary endpoint readouts from the first Phase 3 trials for ORIC-944 and enozertinib (ORIC-114) are expected in 2026 [1][2] Clinical Development Updates - ORIC-944 is a potent allosteric inhibitor of PRC2, with provisional recommended Phase 2 doses selected for testing in combination with darolutamide and apalutamide [3] - Preliminary data from the Phase 1b trial showed significant PSA responses, with 55% of patients achieving a PSA50 response and 20% achieving a PSA90 response [3] - ctDNA analysis indicated that 76% of patients achieved over 50% reduction, with 59% achieving ctDNA clearance, surpassing previous standard care results [3] - Safety profiles for both combination regimens were compatible with long-term dosing, with most adverse events being Grade 1 or 2 [3] Financial Performance - For Q3 2025, R&D expenses were $28.8 million, a decrease from $31.2 million in Q3 2024, attributed to lower drug manufacturing costs [7][9] - General and administrative expenses increased to $7.9 million for Q3 2025, compared to $7.1 million in Q3 2024 [8][9] - The net loss for Q3 2025 was $32.6 million, slightly improved from a loss of $34.6 million in Q3 2024 [15] Upcoming Milestones - ORIC anticipates data milestones for ORIC-944 and enozertinib, with combination dose optimization data expected in Q1 2026 and various data presentations scheduled for December 2025 and mid-2026 [6][8]

Core Insights - ORIC Pharmaceuticals announced additional efficacy and safety data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors for metastatic castration-resistant prostate cancer (mCRPC) [1][2] Efficacy Data - The trial demonstrated a 55% PSA50 response rate and a 20% PSA90 response rate among patients [6] - Rapid and deep circulating tumor DNA (ctDNA) reductions were observed in 76% of patients, with 59% achieving ctDNA clearance, indicating potential long-term treatment benefits [1][7] - PSA responses and ctDNA reductions were consistent across all ORIC-944 dose levels and in combination with both apalutamide and darolutamide [4][5] Safety Profile - The combination of ORIC-944 with apalutamide or darolutamide showed a safety profile compatible with long-term dosing, with most adverse events being Grade 1 or 2 [8] - As of the cutoff date, only one patient experienced a Grade 3 treatment-related adverse event, with no Grade 4 or 5 adverse events reported [8] Next Steps - ORIC has selected provisional recommended Phase 2 doses for ORIC-944 to be tested in combination with darolutamide and apalutamide, with ongoing enrollment in the dose optimization portion of the trial [9] - Preliminary dose optimization data is expected to be announced in Q1 2026, ahead of initiating the first global Phase 3 registrational trial in mCRPC in the first half of 2026 [2][9] Company Overview - ORIC Pharmaceuticals is focused on developing treatments that address mechanisms of therapeutic resistance in cancer, with ORIC-944 being an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) [11]

Summary of Oric Pharmaceuticals FY Conference Call Company Overview - **Company**: Oric Pharmaceuticals (NasdaqGS:ORIC) - **Industry**: Clinical stage oncology - **Mission**: Overcoming Resistance in Cancer - **Focus Areas**: Prostate cancer, lung cancer, and breast cancer - **Clinical Programs**: - **ORIC-944**: Allosteric PRC2 inhibitor for prostate cancer in combination with apalutamide and daralutamide - **ORIC-114**: Selective brain penetrant EGFR HER2 exon 20 program for non-small cell lung cancer [2][3] Financial Position - **Cash and Investments**: $436 million as of Q2, providing a runway into the second half of 2028, assuming success in clinical programs [3] Clinical Development Insights - **ORIC-944**: - Targets AR-dependent tumors transitioning to AR-independent states, aiming to resensitize them to AR inhibitors [4] - Clinical data from competitors (e.g., Pfizer) shows significant improvements in progression-free survival (PFS) with PRC2 inhibitors [6][7] - Pfizer's data indicated a tripling of PFS benefit in certain patient populations, validating the mechanism [7][8] - **Physician Feedback**: - Positive feedback on the randomized control study by Pfizer, indicating a promising profile for new agents in prostate cancer [10][11] - **Comparative Data**: - ORIC-944 shows higher PSA response rates and better safety profiles compared to Pfizer's mevrometostat [13][14] - ORIC-944 designed specifically for prostate cancer with optimized drug properties [14][15] Market Opportunity - **Prostate Cancer Market**: - Significant unmet need with a large patient population; existing AR inhibitors generated $11 billion in sales last year [16][17] - Even with a similar profile to competitors, the market opportunity remains substantial due to the high number of patients [17][18] Phase III Trials - **Timeline**: Planning to start the first phase III study in the first half of next year, approximately 18 months behind Pfizer [18][32] - **Patient Population**: Focus on post-abiraterone patients, with expectations for FDA labeling to reflect this [33][34] EGFR Program (ORIC-114) - **Upcoming Updates**: Data expected at ESMO Asia, focusing on three patient populations: EGFR exon 20, HER2 exon 20, and EGFR atypical [38] - **Benchmarks**: Expected response rates of 35% for EGFR exon 20 and atypicals, and 50% for HER2 exon 20 in second-line settings [39] Combination Therapy - **Amivantamab Collaboration**: Exploring combination therapy with Amivantamab, leveraging its success in classical EGFR settings [42][43] - **Rationale**: Aiming for dual inhibition of EGFR to manage safety and potentially extend PFS and overall survival [43] Conclusion - Oric Pharmaceuticals is positioned to capitalize on significant market opportunities in oncology, particularly in prostate cancer and lung cancer, with promising clinical data and a strong financial position to support ongoing and future trials. The company is focused on differentiating its therapies through optimized drug properties and strategic collaborations.

Core Insights - ORIC Pharmaceuticals, Inc. has granted inducement equity awards to a new non-executive employee as part of its 2022 Inducement Equity Incentive Plan [1][2][3] Summary by Sections Inducement Grants - A total of 18,400 non-qualified stock options and 3,000 restricted stock units were granted on November 3, 2025, to a new employee who started in October 2025 [1] - The stock options have an exercise price equal to the closing price of ORIC's common stock on the Grant Date [2] - Vesting schedule includes 25% of stock options vesting on the one-year anniversary, with the remaining shares vesting monthly thereafter, and one-third of restricted stock units vesting on each of the first three anniversaries [2] Compliance and Approval - The inducement grants were approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4) [3] - The grants were made as a material inducement to employment, complying with Nasdaq regulations [3] Company Overview - ORIC Pharmaceuticals is focused on developing treatments for therapeutic resistance in cancer, with clinical candidates including ORIC-944 for prostate cancer and enozertinib (ORIC-114) targeting various genetically defined cancers [4]

Core Insights - ORIC Pharmaceuticals presented promising preclinical data for ORIC-944, a selective allosteric inhibitor of PRC2, at the 2025 EORTC-NCI-AACR conference, indicating its potential in treating prostate cancer and other solid tumors [1][2] Group 1: ORIC-944 Overview - ORIC-944 is characterized as a potent and selective allosteric PRC2 inhibitor, demonstrating best-in-class drug properties in preclinical studies, including favorable pharmacokinetics and a clinical half-life of approximately 20 hours [4][5] - The drug has shown positive interim PSA response data in ongoing Phase 1b trials, both as a single agent and in combination with other treatments for prostate cancer [4][5] Group 2: Mechanism and Efficacy - PRC2 inhibition has been shown to enhance the response to AR inhibitors, delaying treatment relapse in castration-sensitive prostate cancer by restricting tumor cell adaptation [3][5] - In preclinical models, ORIC-944 combined with KRAS inhibitors significantly improved efficacy and progression-free survival in KRAS G12C mutant non-small cell lung cancer and colorectal cancer, indicating its ability to prevent or delay resistance [5] Group 3: Clinical Development and Future Potential - The company continues to believe that ORIC-944 has the potential to be a best-in-class PRC2 inhibitor, with applications in both castration-resistant and castration-sensitive prostate cancer, as well as other tumor types [2][5] - ORIC Pharmaceuticals is dedicated to overcoming resistance in cancer, with ORIC-944 being a key candidate in their clinical stage pipeline [6]